Search Results
Novel agents vs. standard chemotherapy for first-line salvage treatment following CAR-T in LBCL
New and Novel Agents for DLBCL: Bispecifics, CAR-T, and More
Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL
CAR-T Cell Therapy and Other Novel Therapies for Lymphoma
Salvage therapies superior to chemotherapy in post-transplant r/r cHL
Expert Tips for Using CAR T-Cell Therapy in Leukemia, Lymphoma, and Multiple Myeloma Care
Sattva Neelapu, MD, speculates on the future of first-line CAR T-cell therapy in lymphoma
Novel Therapies in Aggressive Lymphoma & CAR T-cell Therapy
Auto-transplant vs CAR-T: How should we sequence the therapy; who should receive therapy?
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
2022 West Oncology Conference | Treatment Sequencing in Relapsed/Refractory DLBCL in Era of CAR-T
CD19 Targeted CAR T-cell Therapy in LBCL
